Express Mail Label No.: EV399525733US Date of Deposit: April 6, 2004

o 6 2004 Bease type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	10/600,132
	Filing Date	06/19/03
INFORMATION DISCLOSURE	First Named Inventor	Miller and Richon
STATEMENT BY APPLICANT	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	24852-501 CIP

	,:						
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
/YV/	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
ī	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Brestow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
7/	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
\mathbf{V}^-	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

į.					FOREIGN PATENT DOCUMENTS				
	Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Transl Yes	ation No	
7	YX//	B1*	wo	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X		
Ī	X	B2*	wo	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X		
	X	B3*	wo	00/71703	Methylgene, Inc.	November 30, 2000	X		
	1	B4*	wo	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	х		
	у	B5*	wo	01/38322	Methylgene, Inc.	May 31, 2001	Х		
	1	B6*	wo	01/70675	Methylgene, Inc.	September 27, 2001	X	-	
	*	B7*	wo	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	х		
_	1	B8*	wo	02/30879	Prolifix Limited	April 18, 2002	Х		
1	V	B9*	wo	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	Х		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/YW/ C1*		Andrews et al. (2000). Intl. J. Parasitol. 30: 761-768.
17	C2*	Archer et al. (1998). Proc. Natl. Acad. Sci. USA 95: 6791-6796.
₹	C3.	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract 4611.
.(C4*	Butler et al. (2000). Cancer Res. 60: 5165-5170.
γ C5*		Butler et al. (2001). Clincal Cancer Res. 7: 962-970.
		Butler et al. (2002). Proc. Natl. Acad. Sci. USA 99: 11700-11705.
\mathbf{V}_{c}	C7*	Coffey et al. (2000). Medical and Pediatric Oncology 35: 577-581.

Express Mail Label No.: EV399525733US Date of Deposit: April 6, 2004

Vac Coffey et al. (2001). Cancer Res. 91: 3591-3594. X C3° Cohen et al. (1999). Anticancer Res. 19: 4999-5006. X C10° Cohen et al. (2002). Anticancer Res. 22: 1497-1504. X C11° Curlin (2002). Exp. Opin. Ther. Patents 12: 1375-1384. X C12° Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). *Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxam Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos American Society of Hematology, 44° Meeting of the American Society of Hematology, 44° Meeting of the American Society of Hematology, Abstract No. 4602. C14° Apoptosis of Multiple Myeloma Cells. *American Society of Hematology, 44° Meeting of the Am Society of Hematology, Abstract No. 3195. X C15° Finnin et al. (1993). Nature 491: 188-193. X C16° Furamai et al. (2001). *Proc. Natl. Sci. USA 98: 87-92. X C17' Grunstein (1997). Nature 389: 349-352. Y C17' Grunstein (1997). Nature 389: 349-352. Y C18' He et al. (2001). *J. Clin. Investigation 108: 1321-1330. Y C20' Kelly et al. (2003). *Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2001). *Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor. Suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity. *American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). *A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). *European J. Cancer 38(Suppl. 7): 88, Abstract No. 2 (24' Kohge et al. (1998). *Biochem. Pharmacol. 58: 1359-1364. X C28' Kometau et al. (1998). *Biochem. Pharmacol. 58: 1359-1364. X C28' Kometau et al. (2001). *Cancer Res. 51: 4459-4466. X C28' Kometau et al. (2001). *Cancer Res. 51: 491-947. X C31' Marks et al.	Exam	Cite	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
X CS° Cohen et al. (1999). Anticancer Res. 19: 4999-5006. X C 10° Cohen et al. (2002). Anticancer Res. 22: 1497-1504. X C 11° Cohen et al. (2002). Exp. Opin. Ther. Patents 12: 1375-1384. X C 12° Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxa." Acid (SAHA). Ehnances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44° Meeting of the Amarican Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of the New York of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of the New York of Society of Hematology, 184° Meeting of the Amarican Society of Clinical Concentration of the New York of Society of Clinical Concentration of the New York of Society of Clinical Concentration of the New York of Society of Clinical Concentration of th	nitials	No.						
X C10¹ Cohen et al. (2002). Anticancer Res. 22; 1497-1504. X C1²¹ Curfu (2002). Exp. Opin. Ther. Patents 12; 1375-1384. X C1²² Dressel (2000). Anticancer Res. 22; 1017-1022. C13² Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxa Acid (SAHA) Enhances Apo-2L/TRAIL-Induced Death Inducing Signaling Complex and Apoptosis Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract No. 4602. Feinman et al. (2002). The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, In Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the Am Society of Hematology, Abstract No. 3195. X C16¹ Furamai et al. (2001). *Time Histone Deacetylase Inhibitor. Suberoylanilide Hydroxamic Acid, In Apoptosis of Multiple Myeloma Cells." *American Society of Hematology, 44th Meeting of the Am Society of Linical Cell (SAHA), and Individual Cell (SAHA). *Alignation of Meeting of Translation (SAHA). *Alignation of Translation of Meeting of Translation (SAHA). *Alignation of Translation of Transl								
X C11* Curtin (2002). Exp. Opin. Ther. Patents 12: 1375-1384. X C12* Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxa Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology, Atherena Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology, Abstract No. 4602. X C14* Feinman et al. (2002). The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, In Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the Am Society of Hematology, Abstract No. 3195. X C15* Finnin et al. (1999). Nature 401: 188-193. Y C17* Grunstein (1997). Nature 389: 349-352. Y C18* He et al. (2001). To. Natl. Sci. USA 190: 2041-2046. X C19* He et al. (2001). To. Natl. Acad. Sci. USA 190: 2041-2046. X Kelly et al. (2003). Proc. Natl. Sci. USA 190: 2041-2046. X C20* Kelly et al. (2003). Proc. Natl. Sci. USA 190: 2041-2046. X Kelly et al. (2002). "Toxico deacetylase inhibitor, suberoylanilide hydroxamic acid Sci. USA 190: 2041-2046. X C20* Kelly et al. (2002). "Toxico deacetylase inh								
X C12* Dressel (2000). Anticancer Res. 20: 1017-1022. Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxa Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology Abstract No. 4602. Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, In Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the Am Society of Hematology, Nature 401: 188-193. X C15* Finnin et al. (1999). Nature 401: 188-193. X C16* Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. Y C17* Grunstein (1997). Nature 389: 349-352. Y C19* He et al. (2001). *Suberoylanilide Hydroxamic Acid (SAHA), Bitone Deacetylase Inhibitor. Y C20* Kelly et al. (2001). *Suberoylanilide Hydroxamic Acid (SAHA), Bitone Deacetylase Inhibitor, Suberoylanilide Hydroxamic acid (SAHA), Bito								
Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxa Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptos Human Acute Lymphold Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology Abstract No. 4602. Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, In Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the Am Society of Hematology, Abstract No. 3195. X C15* Finnin et al. (1999). Nature 401: 188-193. X C16* Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. C17* Grunstein (1997). Nature 393: 349-352. Y C17* Heckly et al. (2001). J. Clin. Investigation 108: 1321-1330. Y C19* Hockly et al. (2001). J. Clin. Investigation 108: 1321-1330. Y C19* Hockly et al. (2001). Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 71, 2002, Abstrat 1831. Y C22* Kim et al. (1999). Oncogene 18: 2461-2470. Y C24* Kohge et al. (2001). Suberoylanilide Hydroxamic Society of Clinical Oncology, November 71, 2002, Abstrat 1831. Y C25* Komatsu et al. (2001). Cancer Res. 51: 4459-4466. Y C26* Komatsu et al. (2001). Cancer Res. 61: 831-934. Y C27* Lee et al. (2001). Cancer Res. 61: 831-934. X C28* Lin et al. (1998). Nature 391: 811-814. X C29* Mai et al. (2001). Cancer Res. 61: 831-934. X C30* Marks et al. (2001). Cinical Cancer Res. 2: 759-760. X C31* Marks et al. (2001). Cancer Res. 61: 831-934. X C32* Marks et al. (2001). Cancer Res. 61: 839-839-807. X C34* Miller et al. (2001). Cancer Res. 61: 839-839-807. X C36* Minch et al. (2001). Cancer Res. 61: 839-839-807. X C36* Richon et al. (1998). Proc. Nat								
Acid (SAHA) Enhances Apo-2LTRAIL-induced Death Inducing Signaling Complex and Apoptos Human Acute Lymphoid Leukemia Cells." American Society of Hematology, 44th Meeting of the American Society of Hematology Abstract No. 4602. C14* C14* C14* Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44th Meeting of the Am Society of Hematology, Abstract No. 3195. C15* Finnin et al. (1999). Nature 301: 188-193. C16* Firman et al. (2001). Proc. Natl. Sci. USA 38: 87-92. C16* Furamai et al. (2001). Proc. Natl. Sci. USA 38: 87-92. C16* He et al. (2001). J. Clin. Investigation 108: 1321-1330. C19* Hockly et al. (2001). Proc. Natl. Sci. USA 100: 2041-2046. Kelly et al. (2001). Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor. Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), and administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstratian Annual Meeting of the American Society of Clinical Oncology, December 6-10, 2 Marks et al. (2001). Cancer Res. 61: 931-934. C22* Kelly et al. (2003). Meeting of the American Society of Clinical Oncology, D	×	C12*						
\(\times \text{C14*} \) Apoptosis of Multiple Myeloma Cells." American Society of Hematology, 44 th Meeting of the Am Society of Hematology, Abstract No. 3195. \(\times \text{C15*} \) Finnin et al. (1999). Nature 401: 188-193. \(\times \text{C16*} \) Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. \(\times \text{C17*} \) Grunstein (1997). Nature 389: 349-352. \(\times \text{C18*} \) He et al. (2001). J. Clin. Investigation 108: 1321-1330. \(\times \text{C19*} \) Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. \(\times \text{Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. \(\times \text{Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstra 1831. \(\times \text{C22*} \) Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhib suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: 4000 (Cata) Suberoylanilide hydroxamic acid (SAHA). European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: 4000 (Cata) Suberoylanilide hydroxamic acid (SAHA). European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: 4000 (Cata) Suberoylanilide hydroxamic acid (SAHA). Subero	Ý	C13*	Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the					
X C16* Furamai et al. (2001). Proc. Natl. Sci. USA 98: 87-92. Y C17* Grunstein (1997). Nature 389: 349-352. Y C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. Y C19* Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor. Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstrat 1831. Y C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhib suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 20 Y C23* Kim et al. (1998). Biochem. Pharmacol. 56: 1359-1364. C26* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. Y C26* Komtakiis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. X C27* Lee et al. (2001). Cancer Res. 61: 931-934. X C28* Mal et al. (2001). OPPI Briefs 33: 391-394 X	X,	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195 .					
Y C17* Grunstein (1997). Nature 389: 349-352. Y C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. Y C19* Hockly et al. (2001). Forc. Natl. Acad. Sci. USA 100: 2041-2046. X Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology, November 7-10, 2002, Abstrat 1831. Y C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhib suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: 40. 22. C24* Y C23* Kim et al. (1999). Oncogene 18: 2461-2470. Y C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. Y C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. Y C26* Korvaklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. X C27* Lee et al. (2001). OPPI Briefs 33: 391-394. X C28* Lin et al. (2001). OPPI Briefs 33: 391-394. X C31* Marks et	X	C15*	Finnin et al. (1999). <i>Nature</i> <u>401</u> : 188-193.					
Υ C18* He et al. (2001). J. Clin. Investigation 108: 1321-1330. Υ C19* Hockly et al. (2003). Proc. Natl. Acad. Sci. USA 100: 2041-2046. Υ C20* Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstrat 1831. Y C22* Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhib suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: With the suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: With the suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 2: With the suberoylanilide hydroxamic acid (SAHA)." European J. Cancer Agents 2: 477-484. Y C22* Kohge et al. (1999). Biochem. Pharmacol. 56: 1359-1364. Y C25* Komatsu et al. (2001). Cancer Res. 61: 34459-4466. Y C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. X C27* Lee et al. (2001). Cancer Res. 61: 33: 391-394. X C28*		C16*						
C19* Hockly et al. (2001). Proc. Natl. Acad. Sci. USA 100: 2041-2046. C20* Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." American Society of Clinical Oncology, Abstract No. 344. Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), oral administered has good bioavailability and biologic activity." American Society of Clinical Oncology 38th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstrat 1831. Y	Υ	C17*						
C20* Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." *American Society of Clinical Oncology, Abstract No. 344.	Y	C18*						
C21	4	C19*						
Administered has good bioavailability and biologic activity." American Society of Clinical Oncology 3th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstrated 1831. Y	4	C20*						
Y C22¹ suberoylanilide hydroxamic acid (SAHA)." European J. Cancer 38(Suppl. 7): 88, Abstract No. 20 Y C23¹ Kim et al. (1999). Oncogene 18: 2461-2470. ✓ C24¹ Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. ✓ C25¹ Komatsu et al. (2001). Cancer Res. 61: 4459-4466. ✓ C26¹ Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. ✓ C27¹ Lee et al. (2001). Cancer Res. 61: 931-934. X C28¹ Lin et al. (1998). Nature 391: 811-814. ✓ C29¹ Mai et al. (2001). OPPI Briefs 33: 391-394 X C30¹ Marks et al. (2001). Clinical Cancer Res. 7: 759-760. X C31¹ Marks et al. (2001). Clinical Cancer Res. 7: 759-760. X C32¹ Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. Y C33¹ Marks et al. (2001). Nature Reviews 1: 194-202. Y C34¹ Miller et al. (2003). J Med Chem. 46: 5097-5116. Y C35¹ Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin'	₹	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.					
✓ C24* Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364. ✓ C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. ✓ C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. ✓ C27* Lee et al. (2001). Cancer Res. 61: 931-934. X C28* Lin et al. (1998). Nature 391: 811-814. ✓ C29* Mai et al. (2001). OPPI Briefs 33: 391-394 X C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. ✓ C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. ✓ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. ✓ C33* Marks et al. (2001). Nature Reviews 1: 194-202. ✓ C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. ✓ C35* Munster et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. ✓ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C39* Richon et al. (1998). Proc. Natl. Acad	γ′	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> 38(Suppl. 7): 88, Abstract No. 286.					
✓ C25* Komatsu et al. (2001). Cancer Res. 61: 4459-4466. ✓ C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. ✓ C27* Lee et al. (2001). Cancer Res. 61: 931-934. ✓ C28* Lin et al. (1998). Nature 391: 811-814. ✓ C29* Mai et al. (2001). OPPI Briefs 33: 391-394 ✓ C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. ✓ C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. ✓ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. ✓ C33* Marks et al. (2001). Nature Reviews 1: 194-202. ✓ C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. ✓ C35* Munster et al. (2000). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. ✓ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. ✓ C38* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. <	Y	C23*	Kim et al. (1999). Oncogene <u>18</u> : 2461-2470.					
✓ C26* Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484. ✓ C27* Lee et al. (2001). Cancer Res. 61: 931-934. × C28* Lin et al. (1998). Nature 391: 811-814. ✓ C29* Mai et al. (2001). OPPI Briefs 33: 391-394 ✓ C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. ✓ C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. ✓ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. ✓ C33* Marks et al. (2001). Nature Reviews 1: 194-202. ✓ C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. ✓ C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. ✓ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. ✓ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richo	~	C24*	Kohge et al. (1998). Biochem. Pharmacol. 56: 1359-1364.					
X C27* Lee et al. (2001). Cancer Res. 61: 931-934. X C28* Lin et al. (1998). Nature 391: 811-814. X C29* Mai et al. (2000). OPPI Briefs 33: 391-394 Y C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. Y C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. X C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. Y C33* Marks et al. (2001). Nature Reviews 1: 194-202. Y C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. Y C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. C'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	<	C25*	Komatsu et al. (2001). Cancer Res. 61: 4459-4466.					
X C28* Lin et al. (1998). Nature 391: 811-814. X C29* Mai et al. (2001). OPPI Briefs 33: 391-394 X C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. X C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. X C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. X C33* Marks et al. (2001). Nature Reviews 1: 194-202. Y C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. X C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHLO and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	Υ .	C26*	Kouraklis and Theocharis (2002). Curr. Med. Chem.Anti-Cancer Agents 2: 477-484.					
X C29* Mai et al. (2001). OPPI Briefs 33: 391-394 χ C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. χ C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. χ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. χ C33* Marks et al. (2001). Nature Reviews 1: 194-202. γ' C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. χ C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. γ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. χ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	х	C27*	Lee et al. (2001). Cancer Res. 61: 931-934.					
χ C30* Marks et al. (2000). J. of the Natl. Cancer Institute 92: 1210-1215. χ C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. χ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. χ C33* Marks et al. (2001). Nature Reviews 1: 194-202. ζ C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. χ C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. Ο'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. γ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. χ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	×	C28*	Lin et al. (1998). Nature 391: 811-814.					
X C31* Marks et al. (2001). Clinical Cancer Res. 7: 759-760. X C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. X C33* Marks et al. (2001). Nature Reviews 1: 194-202. Y C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. X C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	X	C29*	Mai et al. (2001). OPPI Briefs 33: 391-394					
χ C32* Marks et al. (2001). Curr. Opin. In Oncology 13: 477-483. χ C33* Marks et al. (2001). Nature Reviews 1: 194-202. Υ C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. χ C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. Ο'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Υ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. χ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	X							
X C33* Marks et al. (2001). Nature Reviews 1: 194-202. Y C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. Y C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	X	C31*						
Y C34* Miller et al. (2003). J Med Chem. 46: 5097-5116. Y C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. χ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	X	C32*						
 Y C35* Munster et al. (2001). Cancer Res. 61: 8492-8497. O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Y C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664. 	X							
O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. V C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. X C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	Y	C34*						
Υ C36* hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphom (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2 Abstract No. 4742. Υ C37* Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083. χ C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	ΙΥ	C35*						
χ' C38* Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708. χ C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. χ C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ' C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	Y	C36*	hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." American Society of Clinical Oncology, December 6-10, 2002,					
X C39* Richon et al. (1998). Proc. Natl. Acad. Sci. USA 95: 3003-3007. X C40* Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	Y	C37*	Qui et al. (2000). Mol. Biol. Cell 11: 2069-2083.					
χ C40° Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019. γ C41° Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	χ	C38*	Richon et al. (1996). Proc. Natl. Acad. Sci. USA 93: 5705-5708.					
Y C41* Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.	×	C39*	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> : 3003-3007.					
		C40*	Richon et al. (2000). Proc. Natl. Acad. Sci. USA 97: 10014-10019.					
Y C42* Saito et al (1999) Proc Natl Acad Sci USA 96: 4592-4597	Υ	C41*	Richon and O'Brien (2002). Clinical Cancer Res. 8: 662-664.					
1 1 042 Odito et al. (1995). 1 100. 1488. Addd. Col. COA <u>50</u> . 4052-4051.	¥	C42*	Saito et al. (1999). Proc. Natl. Acad. Sci. USA 96: 4592-4597.					



Express Mail Label No.: EV399525733US


Date of Deposit: April 6, 2004

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
ΛЖ	1	Radiation in Human Prostate Tumor Spheroids." American Society of Clinical Oncology, Abstract No. 105.				
Α,	C44*	Stowell et al. (1995). J. Med. Chem. 38: 1411-1413.				
	C45*	Su et al. (2000). Cancer Res. 60: 3137-3142.				
X	C46*	Suzuki et al. (1999). J. Med. Chem. 42: 3001-3003.				
$\prod \left\langle \cdot \right\rangle$	C47*	Van Lint et al. (1996). Gene Expression 5: 245-253.				
7	C48*	Vrana et al. (1999). Oncogene 18: 7016-7025.				
X	C49*	Webb et al. (1999). J. Biol. Chem. 274: 14280-14287.				
1	C50*	Yoshida et al. (1990). J. Biol. Chem. 265: 17174-17179.				
	C51*	Yoshida et al. (1995). BioEssays 17: 423-430.				
\Box \checkmark	C52*	Zhou et al. (1999). Gene 233: 13-19.				
X	C53*	Zhou et al. (2000). Proc. Natl. Acad. Sci. USA 97: 1056-1061.				
	C54*	Zhou et al. (2000). Proc. Natl. Acad. Sci. USA 97: 14329-14333.				
\mathbf{V}_{\leftarrow}	C55*	Zhou et al. (2001). Proc. Natl. Acad. Sci. USA 98: 10572-10577.				

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature /Yevgeny Valenrod/	Date Considered	01/18/2008
---------------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



NYC 284748v1

Express Mail Label No.: EV942366727US

Date of Deposit: April 18, 2007

type a plus sign (+) in this box +

PTO/SB (12-97) OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Form 1449/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/600,132
Filing Date	June 19, 2003
First Named Inventor	Miller
Group Art Unit / Conf. No.:	1621 / 8627
Examiner Name	Yevgeny Valenrod
Attorney Docket Number	24852-501 CIP

(use as many sheets as necessary)

	U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date	
/YV/	A33	2005/0004007	01/06/05	Grant et al.	514	7	03/05/2003	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No		

NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
/YV/	C139	Rubartelli et al. (1995); "High Rates of Thioredoxin Secretion Correlate with Growth Arrest in Hepatoma Cells"; Cancer Research; Vol. 55, pages 675-680.					

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

	Examiner Signature	/Yevgeny Valenrod/	Date Considered	01/18/2008
ı	·		i	I .

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV942366979US

Date of Deposit: May 23, 2007

/ Please type a plus sign (+) in this box +

PTO/SB (12-97) OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Form 1449/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

10/600,132
June 19, 2003
Miller
1621 / 8627
Yevgeny Valenrod
24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
/YV/	A34	2004/0018968	01/29/04	Sgouros et al.	514	9	04/15/03
/YV/	A35	2006/0167103	07/27/06	Bacopoulos et al.	514	575	03/28/06
/YV/	A36	2006/0276547	12/07/06	Bacopoulos et al.	514	575	07/24/06
/YV/	A37	2007/0060614	03/15/07	Bacopoulos et al.	514	352	11/17/06

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No	
	<u> </u>					

	NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Yevgeny Valenrod/	Date Considered	01/18/2008
-----------------------	--------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail Label No.: EV942367395US

Date of Deposit: July 18, 2007

/ Please type a plus sign (+) in this box	+

PTO/SB (12-97) OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Form 1449/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/600,132
Filing Date	June 19, 2003
First Named Inventor	Miller
Group Art Unit / Conf. No.:	1621 / 8627
Examiner Name	Yevgeny Valenrod
Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No		

	NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
ſYVI	C140	Phase I clinical trial of oral suberoylanilide hydroxamic acid - SAHA (msk390) in patients with advanced solid tumors and hematologic malignancies; first patient dosed in August 2001 at Memorial Sloan Kettering Cancer Center. SAHA gelatin capsules containing SAHA and excipients were administered to patients. The SAHA was prepared according to methods in Example 1 of U.S. application 10/379,149.				
/YV/	C141	Copy of February 2, 2007 Office Action in USSN 10/379,149.				

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Yevgeny Valenrod/	Date Considered	01/18/2008	
-----------------------	--------------------	--------------------	------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.